Abstract
With the increasing number of transgender and gender diverse (TGD) individuals who are seeking gender-affirming care, there is a clear need for the development and collection of evidence-based data to establish guidelines for patient care. TGD individuals are estimated to represent 0.3 to 4.5% of the world population. Gender-affirming care that includes hormone therapy helps to align the body of a transgender person with their gender identity. Hormone therapy requires monitoring for both safety and efficacy. The extent to which gender-affirming hormone therapy alters cancer risk remains unknown. Because of a lack of comprehensive data collection pertaining to this patient population, endocrine cancer data including incidence and outcomes is limited. Dedicated research is needed to help address the gap in knowledge pertaining to the risk of cancer in the TGD population.
Original language | English |
---|---|
Article number | e230214 |
Journal | Endocrine-Related Cancer |
Volume | 31 |
Issue number | 2 |
DOIs | |
State | Published - 2024 |
Keywords
- androgen
- carcinoma
- estrogen
- neoplasia
- testosterone